Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Its commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration and retinal vein occlusion.

Employee Rating

4.4More
TypePublic
HQAlpharetta, US
Founded2003
Size (employees)118 (est)-5%
Websitealimerasciences.com
Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman

Philip Ashman

SVP & European Managing Director
Rick Eiswirth

Rick Eiswirth

President & CFO
Dave Holland

Dave Holland

SVP of Sales & Marketing
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Lisbon, Hampshire and Berlin
Alpharetta, (HQ)
6120 Windward Pkwy
Berlin,
21 Cicerostraße
Hampshire,
Wellesley Rd
Show all (4)
Report incorrect company information

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $35.91 m in FY, 2017
USD

Revenue (Q3, 2018)

11.1m

Net income (Q3, 2018)

(3.4m)

EBIT (Q3, 2018)

(2.2m)

Market capitalization (4-Dec-2018)

70.8m

Closing stock price (4-Dec-2018)

1.0

Cash (31-Dec-2017)

24.1m

EV

81.1m
Alimera Sciences's current market capitalization is $70.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.9m8.4m22.4m34.3m35.9m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m

Gross profit

9.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m

Cost of goods sold

57.0k564.0k376.0k

Gross profit

701.0k1.5m1.8m

Gross profit Margin, %

92%73%83%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

12.6m76.7m31.1m31.0m24.1m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m

Inventories

1.8m3.2m1.6m446.0k1.5m

Current Assets

18.6m83.3m45.2m47.4m39.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

23.1m41.3m42.0m61.4m61.3m48.1m39.3m23.9m16.6m33.9m26.7m26.9m25.6m

Accounts Receivable

464.0k1.3m1.0m1.1m3.4m7.7m9.4m9.1m13.3m13.4m10.8m13.6m13.5m

Inventories

3.0m1.2m1.4m1.7m2.1m1.6m1.7m1.4m1.2m913.0k802.0k1.1m1.7m

Current Assets

30.1m46.5m47.5m67.3m70.3m61.1m53.4m37.2m34.7m51.6m40.5m44.3m43.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46.2m)(35.9m)(30.6m)(33.2m)(22.0m)

Depreciation and Amortization

138.0k659.0k2.6m2.8m2.7m

Inventories

(1.4m)206.0k(386.0k)1.0m(1.1m)

Accounts Payable

(259.0k)3.0m(487.0k)1.1m644.0k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(31.5m)(20.8m)(19.6m)(26.7m)(9.8m)(18.4m)(19.9m)(11.1m)(18.0m)(27.2m)(6.7m)(9.5m)(14.8m)(7.7m)(11.7m)(15.1m)

Depreciation and Amortization

101.0k36.0k69.0k151.0k558.0k1.2m1.9m689.0k1.4m2.1m666.0k1.3m2.0m649.0k1.3m1.9m

Inventories

(2.2m)548.0k400.0k(9.0k)(455.0k)(16.0k)(88.0k)164.0k301.0k612.0k(361.0k)(719.0k)(1.3m)299.0k(651.0k)(250.0k)

Accounts Payable

717.0k111.0k122.0k1.3m272.0k(1.2m)(1.4m)(1.5m)264.0k(2.1m)(1.1m)572.0k98.0k(992.0k)167.0k(779.0k)
Show all financial metrics
Report incorrect company information

Alimera Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alimera Sciences News and Updates

Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

ATLANTA, Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN® usage in Europe and the U.S. will be ...

Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

ATLANTA, Sept. 13, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN® during the ...

Global Diabetic Macular Edema Treatment Market 2018-2022 - Key Vendors are Allergan Alimera Sciences, Bausch Health, F. Hoffmann-La Roche & Regeneron Pharmaceuticals

DUBLIN, Sept 11, 2018 /PRNewswire/ -- The "Global Diabetic Macular Edema Treatment Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Diabetic Macular Edema Treatment Market to grow at a CAGR of 1.45% during the period 2018-2022. Global Diabetic...

Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

ATLANTA, Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates...

Alimera Sciences Reports Second Quarter 2018 Results

ATLANTA, July 30, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three months ended June...

Alimera Sciences Appoints Mary T. Szela to its Board of Directors

ATLANTA, June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief...
Show more
Report incorrect company information

Alimera Sciences Blogs

Alimera Sciences to Present at Upcoming Investor Conferences

ATLANTA, GA / ACCESSWIRE / November 9, 2018 /  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, Chief Executive Officer, will be presenting at the following investor

Alimera Sciences Reports Third Quarter 2018 Results

Monday, November 5, 2018 7:45 PM Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November 5, 2018 / Alimera Sciences, Inc.

Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

ATLANTA, October 23, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2018, after the close of the

Alimera Sciences Announces Six ILUVIEN® Posters to be Presented at 2018 American Academy of Ophthalmology

ATLANTA, October 22, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that six posters on ILUVIEN ® will be available during the 2018 Annual Meeting of the American Academy of

Mary T. Szela

Mary T. Szela Matthew.Callan… Thu, 07/19/2018 - 13:20 Member of the Audit Committee Charter Mary T. Szela, M.B.A., B.S.N. Chief Executive Officer and President, Surefire Medical, Inc. Mary T. Szela, M.B.A., has been a member of our board of directors since 2018. …

Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

ATLANTA, July 18, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018, after the close of the

Alimera Sciences Company Life and Culture

Report incorrect company information

Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Susan Caballa and Philip Ashman.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 118 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $35.9 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $304.3 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Lisbon, Hampshire and Berlin.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 4 offices.